2Baldwin SL, D'Souza C, Roberts AD, et al. Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis [J].Infect Immun,1998,66(6) :2951--2959.
4Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo [J]. Science, 1990,247(4949 Pt 1):1465--1468.
5Tanghe A, Content J, Van Vooren JP, et al. Protective efficacy of a DNA vaccine encoding antigen 85A from mycobacterium bovis BCG against buruli ulcer [J]. Infect Immun,2001,69 (9) :5403--5411.
6Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual [M]. 2nd. New York: Cold Spring Harbor Laboratory Press, 1992,16--69.
7Zlotta AR,Van Vooren JP,Denis O, et al. What are the immunologically active components of bacilli Calmette-Guerin in therapy of superficial bladder cancer [J]. Int J Cancer, 2000,87(6):844--852.
8ZlottaAR, Drowar A, Van Vooren JP, et al. Superficial bladder tumors and increased reactivity against myobacterial antigens before bacillus Calmette-Guerin therapy [J]. J Urol. 1998,159(6):1885--1891.
9GomellaLG, MasterangeloMJ, McCue PA, et al. Phase I study of intravesical vacciniavirus as a vector for gene therapy of bladder cancer [J]. J Urol, 2001,166(4),1291--1295.
10Scientific blueprint for TB drug development, the Global Alliance for TB Drug Development forum. 2001,1-52.
1Luzzi VI,Scott MG,Gronowski AM.Negative thyrotropin assay interference associated with an IgGkappa paraprotein[J].Clin Chem,2003,49(4):709-710.
2Alito A,McNair J,Girvin RM,et al.Identification of Mycobacterium bovis antigens by analysis of bovine T-cell responses after infection with a virulent strain[J].Braz J Med Biol Res,2003,36(11):1 523-1 531.
